Mila Ayash-Rashkovsky

Director Clinical Programs
Takeda Development Center Americas, Inc., Cambridge, MA, USA
Cambridge, Massachusetts, United States

Presentation(s):

• OC 14.1 - Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura

  Sunday, June 25, 2023
  10:45 – 11:00 ET